CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast CancerMelani Luque(Hospital Universitario Fundación Jiménez Díaz), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz)Journal of Clinical MedicineMarch 14, 202210.3390/jcm11061610Cited by 7SaveCiteExport RISWatch citationsRelated PapersPhase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer|Journal of Clinical Oncology|2005|409PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects|Oncotarget|2015|100The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer|Cancers|2020|37